MPR Weekly Dose

MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer

Jun 24, 2021

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Meanwhile, real-world data on the efficacy of the COVID-`9 treatment remdesivir has been published.

MPR Weekly Dose 82 - A regenerative skin therapy; Novavax vaccine shows promise; Mastocytosis treatment; Potential new depression treatment; And an FDA warning for hand sanitizers.

Jun 17, 2021

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax’s vaccine for COVID and a novel treatment for MDD show promise. Also the FDA issue warning concerning hand sanitizers.

MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories

Jun 11, 2021

This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We’ll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12.

MPR Weekly Dose 80 - Migraine prevention treatment; Pediatric combo vaccine; Schizophrenia, Bipolar I approval; AI-based Autism diagnostic

Jun 4, 2021

On this week's show we have news of migraine prevention treatment, a hexavalent vaccine is approved for pediatrics, there’s also an approval for schizophrenia and bipolar I disorder, lumakras gets fast tracked and there’s a new diagnostic aid for Autism, and it is artificial...